Global Cell & Gene Therapy Manufacturing Services Market Analysis 2024 – Estimated Market Size And Key Drivers

The Cell & Gene Therapy Manufacturing Services Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cell & Gene Therapy Manufacturing Services Market:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report

According to The Business Research Company’s Cell & Gene Therapy Manufacturing Services Global Market Report 2024, The cell & gene therapy manufacturing services market size has grown rapidly in recent years. It will grow from $7.25 billion in 2023 to $8.55 billion in 2024 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to increased r&d investments, regulatory support and frameworks, growing pipeline of cell & gene therapies, industry collaborations and partnerships, increasing global demand for personalized medicine.

The cell & gene therapy manufacturing services market size is expected to see rapid growth in the next few years. It will grow to $15.77 billion in 2028 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to market maturation and commercialization, global expansion of biopharmaceutical manufacturing, increased outsourcing by pharma companies, advancements in automation and robotics, emergence of new therapeutic modalities. Major trends in the forecast period include rising demand for energy efficiency, advanced materials and technologies, compact and modular designs, electrification of transportation, focus on safety and reliability.

The high incidence of cancer and other target diseases is expected to propel the growth of the cell and gene therapy manufacturing services market going forward. Cancer is a severe disorder in which the body’s cells reproduce fast and uncontrollably, resulting in abnormal growth. Cell and gene therapies are developing as promising new strategies to combat the rising incidence of cancer, which is driving the demand for novel and efficient treatment choices. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. , Therefore, the high incidence of cancer and other target diseases is driving the growth of the cell and gene therapy manufacturing services market going forward.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10035&type=smp

The cell & gene therapy manufacturing services market covered in this report is segmented –

1) By Type: Gene Therapy, Cell Therapy
2) By Indication: Central Nervous System Disorders, Ophthalmology Diseases, Cardiovascular Diseases, Infectious Diseases, Orthopaedic Diseases, Oncology Diseases
3) By Application: Commercial Manufacturing, Clinical Manufacturing
4) By End-user: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Technological advancements are a key trend gaining popularity in the cell and gene therapy manufacturing services market. Major companies operating in the cell and gene therapy manufacturing services market are adopting new technologies to sustain their position in the market. For instance, in October 2022, Charles River Laboratories International Inc., a US-based pharmaceutical company specializing in various preclinical and clinical laboratory, gene therapy, and cell therapy services, launched the navigation Vector Platform (navigation). It is a platform that simplifies the path to GMP Adeno-Associated Virus (AAV) vector manufacturing without requiring extensive process development. Compared to standard manufacturing workflows, the navigation platform can cut a program’s timeframe to GMP by 55% for viral vector gene therapy researchers. Charles River’s navigation technique is based on a unique high-productivity HEK293 suspension cell line that can be scaled up and serotyped to meet clients’ needs.

The cell & gene therapy manufacturing services market report table of contents includes:

1. Executive Summary
2.Cell & Gene Therapy Manufacturing Services  Market Characteristics
3.Cell & Gene Therapy Manufacturing Services  Market Trends And Strategies
4.Cell & Gene Therapy Manufacturing Services  MarketMacro Economic Scenario
5. Cell & Gene Therapy Manufacturing Services Market Size And Growth
6.Cell & Gene Therapy Manufacturing Services  Segmentation
7.Cell & Gene Therapy Manufacturing Services  Regional And Country Analysis
.
.
.
27.Cell & Gene Therapy Manufacturing Services  Competitive Landscape And Company Profiles
28.Cell & Gene Therapy Manufacturing Services  Key Mergers And Acquisitions
29.Cell & Gene Therapy Manufacturing Services  Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Charles River Laboratories International Inc.
• Lonza Group AG
• Catalent Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model